HIV

Ibalizumab-uiyk (Trogarzo, Theratechnologies) is an injectable CD4-directed post-attachment HIV-1 inhibitor for the treatment of HIV type 1 infection in heavily treatment-experienced adults.

There are other courses available on HIV, but PQA's surveys the 13 medication related quality measures out there for HIV.

The FDA previously placed a clinical hold on lenacapavir in borosilicate vials in all clinical studies because of emerging concerns about the compatibility of vials made of borosilicate glass.

After 14 months without ART, a patient with HIV only had transient detection of trace levels of HIV DNA in her blood cells after a stem cell transplant for acute myeloid leukemia.

Results of a meta-analysis of randomized clinical trials published in JAMA shows improvement in 6 of 8 domains.

Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration.

Letermovir has been approved by the FDA to prevent severe CMV in patients who are asymptomatic and undergoing allogeneic hematopoietic stem cell transplants.

PrEP use has been associated with lowering HIV infections worldwide, however use of the treatment alone is not sufficient to prevent HIV from spreading.

Cabotegravir is the only current HIV-1 PrEP medication that does need to be taken daily.

A panel of experts discuss the role of PrEP in HIV prevention with a focus on current and newly approved options.

Triumeq is a tablet containing 50 mg of dolutegravir, 600 mg of abacavir, and 300 mg of lamivudine.

FDA approves expanded indication for the treatment of HIV-1 in virologically suppressed adolescents 12 years of age or older, who weigh at least 35 kg, and who are on a stable antiretroviral regimen, with no history of treatment failure or known or suspected resistance to either cabotegravir or rilpivirine.

Ibalizumab-uiyk (Trogarzo) is a CD4-directed post-attachment HIV-1 inhibitor.

FDA approves label update for Cabenuva that makes the therapy’s oral lead-in with cabotegravir and rilpivirine tablets optional.

The FDA recently approved cabotegravir 200 mg/mL and rilpivirine 300 mg/mL as a once-monthly treatment for adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen.

Moderna is currently evaluating 2 HIV vaccine strategies that involve germline targeting and immune-focusing approaches.

Enhanced tools in the field of structural biology may reveal new insights into HIV that could lead to a vaccine to protect against the virus progessing to AIDS.

New strategies are needed to increase HIV prevention and testing efforts among high-risk communities.

PrEP involves taking emtricitabine/tenofovir (Truvada or Descovy) to prevent high-risk individuals from contracting HIV.

The results of a new study indicate that early initiation of treatment with combined antiretroviral therapy (cART) leads to better outcomes in patients coinfected with HIV and tuberculosis (TB).

Data from the CALIBRATE and CAPELLA trials show high rates of virologic suppression with the capsid inhibitor.

Through the 240 weeks, numerically small median changes in eGFR and stable TC:HDL ratios were observed in both studies.

The use of a unique trimer to produce tier-2 neutralizing antibodies may help fight HIV.

Effective pre-exposure prophylaxis limits the additional price that payers should be willing to pay for the pre-exposure prophylaxis, investigators say.

Although COVID-19 vaccination rates have increased since the survey was initially conducted, the researchers noted that their results are important when considering the possibility of an annual COVID-19 vaccine.

Medication can now be used as few as 6 times a year for virologically suppressed adults living with the disease without prior treatments not working or resistance to cabotegravir or rilpivirine.

The analysis of 204 countries and territories reveals that AMR is now a leading cause of death worldwide, which is higher than HIV/AIDS or malaria.

These findings suggest people with indications for PrEP may confront an access barrier if they live in a state that restricts scope of practice, according to the study.

Fostemsavir (Rukobia) is indicated in combination with other antiretroviral medications in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.

Cabotegravir (Apretude) is indicated for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection.